1. Bristol Myers to build first cell therapy factory in Europe — Teva CEO Schultz sees a 35% raise despite company's legal woes — Why Biogen Q1 earnings weren't good enoughSee more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Latest News - ADU won't be approved

Discussion in 'BiogenIdec' started by anonymous, Oct 19, 2020 at 9:26 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    "Alzheimer's treatment is a huge, urgent, unmet need. But I also think that if we approved something where the data is not strong, that we have a risk of delaying an effective treatment for more than a couple of years," said one of the panelists, Joel Perlmutter, a professor of radiology and neuroscience at the Washington University School of Medicine.

    "I think there's a huge danger in approving something that turns out not to be effective," he added.

  2. anonymous

    anonymous Guest

    He needs to be investigated as some say he is planning on leaving FDA and going into industry?
  3. anonymous

    anonymous Guest

  4. anonymous

    anonymous Guest

    Profile my ass. This drug has no chance of approval. I’m budding up the resume and going to double dip like I did at my last company if I find something before the layoffs begin